1-7 of 7
Yanfeng Wang, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparison of Steady-State Imatinib (IM) Trough Levels, Clinical Response, and Safety Between Caucasian and Asian Patients with Chronic Lyeloid Leukemia in Chronic Phase (CML-CP) Treated with 400mg and 800mg Daily Doses of IM in the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) Study.

Dong-Wook Kim, MD, PhD, Camille Granvil, PhD, Eren Demirhan, John Reynolds, Yu Jin, MSc, Yanfeng Wang, PhD, Michele Baccarani, MD, Jorge Cortes-Franco, MD, Brian J. Druker, MD, Timothy P. Hughes, MD, MBBS, François Guilhot, MD
Journal: Blood
Blood (2009) 114 (22): 1127.
https://doi.org/10.1182/blood.V114.22.1127.1127
Published: 2009
Journal Articles

Steady-State Imatinib Trough Levels as Well as Dose Interruptions Are Associated with Clinical Response (CCyR and MMR) and Adverse Events (AEs) in Patients with Chronic Myeloid Leukemia (CML) Receiving IM as Frontline Therapy.

Richard A. Larson, MD, Yen Lin Chia, PhD, Camille Granvil, PhD, François Guilhot, MD, Brian J. Druker, MD, Stephen G O'Brien, MD, PhD, Michele Baccarani, MD, Timothy P. Hughes, MD, MBBS, Jerry R. Nedelman, PhD, Yanfeng Wang, PhD
Journal: Blood
Blood (2009) 114 (22): 2213.
https://doi.org/10.1182/blood.V114.22.2213.2213
Published: 2009
Journal Articles

Imatinib (IM) Pharmacokinetic (PK) Exposure and Its Correlation with Clinical Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) for 400 Mg and 800 Mg Daily Doses (Tyrosine Kinase Dose Optimization Study [TOPS])

François Guilhot, MD, Timothy P Hughes, MD, Jorge Cortes, MD, Yanfeng Wang, PhD, Michael Hayes, PhD, Anthony Gichangi, PhD, Brian J. Druker, MD, Michele Baccarani, MD
Journal: Blood
Blood (2008) 112 (11): 447.
https://doi.org/10.1182/blood.V112.11.447.447
Published: 2008
Journal Articles

Effects of Imatinib on the Pharmacokinetics of Acetaminophen in Korean Patients with Chronic Myelogenous Leukemia (CML)

Dong-Wook Kim, MD, PhD, Sa-Hee Park, Yu Jin, MS, Michael Hayes, PhD, Yanfeng Wang, PhD
Journal: Blood
Blood (2008) 112 (11): 5056.
https://doi.org/10.1182/blood.V112.11.5056.5056
Published: 2008
Journal Articles

Correlation of Pharmacokinetic Data with Cytogenetic and Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib - An Analysis of IRIS Study Data.

Richard A. Larson, MD, Brian J. Druker, MD, Francois Guilhot, MD, Stephen G. O’Brien, MBChB, PhD, Insa Gathmann, MS, Gilles J. Riviere, PhD, Charlene So, PharmD, Yanfeng Wang, PhD, on Behalf of the IRIS Study Group
Journal: Blood
Blood (2006) 108 (11): 429.
https://doi.org/10.1182/blood.V108.11.429.429
Published: 2006
Journal Articles

Therapeutic Drug Monitoring of Imatinib and Impact on Clinical Decision Making.

Carolyn Blasdel, MA, RN, FNP, Yanfeng Wang, PhD, Theodore Lagattuta, BS, Brian Druker, MD, Laurie Letvak, MD, Merrill Egorin, MD FACP
Journal: Blood
Blood (2006) 108 (11): 4820.
https://doi.org/10.1182/blood.V108.11.4820.4820
Published: 2006
Journal Articles

Pharmacokinetic and Pharmacodynamic Studies of Lestaurtinib (CEP-701) and PKC-412: Cytotoxicity Is Often Dependent on Non-FLT3-Mediated Effects.

Mark Levis, MD, PhD, Adam Stine, BS, Rosalyn, Pham BS, B. Douglas Smith, MD, Judith Karp, MD, Richard Stone, MD, Elihu Estey, MD, Frank Giles, MD, Hagop Kantarjian, MD, Pamela Cohen, MD, Yanfeng Wang, PhD, Donald Small, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 2463.
https://doi.org/10.1182/blood.V106.11.2463.2463
Published: 2005